Compare AbbVie Inc (ABBV) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs TKO Group Holdings Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while TKO Group Holdings Inc trades at $191.99 (market cap $14.51B). The key difference: AbbVie Inc is far larger — about 31× TKO Group Holdings Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | TKO | |
|---|---|---|
Market Cap | $449.91B | $14.51B |
Sector | Health | Technology |
52-Week High | $261.07 | $224.96 |
52-Week Low | $184.85 | $155.61 |
Enterprise Value | $513.38B | $18.69B |
Dividend Yield | 2.72% | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
TKO trades at $192.30, down 1.09% today, with a bearish technical signal. The stock shows mixed earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $4.74B in 2025, with net income of $195.40M, though high P/E of 71.49 suggests premium valuation. Recent news includes a successful WWE-UFC doubleheader and an $800M share repurchase, indicating strong operational momentum.
Outlook remains positive with 84% analyst buy ratings and a $234 consensus target, but risks include earnings volatility and competitive pressures. The stock offers growth potential through live event demand and media deals, yet investors should monitor margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
